The main directions and prospects in polycystic ovary syndrome treatment
https://doi.org/10.18699/SSMJ20210602
Abstract
The article is devoted to the actual gynecological problem of women of reproductive age-polycystic ovarian syndrome (PCOS) and the possibilities of its pharmacotherapy. Difficulties in choosing the treatment of the disease are the need to take into account all clinical manifestations, not limited to menstrual disorders and infertility. PCOS is usually accompanied by hirsutism, obesity, decreased glucose tolerance, and other manifestations in various organ systems associated with metabolic disorders. These manifestations significantly reduce the quality of life of patients and also require pharmacological correction. Currently, the first line of drugs in the treatment of PCOS remains combined oral contraceptives, which have been used by women for decades, but, unfortunately, have multiple adverse reactions. The latter is the reason for the search for other methods of pharmacotherapy that are highly effective and safe. Metformin is one these glucose-lowering drugs, which shows effectiveness in the treatment of PCOS. Drugs from such groups as glucagon-like peptide-1 receptor agonists are at the research stage, and the development of treatment tactics using glucose-lowering drugs that have antagonism to glucagon is continuing. Expanding the choice of pharmacotherapy, thanks to the search for new, more effective and safe drugs and combining it with other treatment methods, makes it possible to control PCOS taking into account the individual characteristics of patients.
About the Authors
A. N. Useinova
Crimean Federal University n.a. V.I. Vernadsky
Russian Federation
Russian Federation
Asie N. Useinova, candidate of medical sciences
295051, Simferopol, Lenin blvd., 5/7
E. A. Egorova
Crimean Federal University n.a. V.I. Vernadsky
Russian Federation
Russian Federation
Elena A. Egorova, candidate of pharmaceutical sciences
295051, Simferopol, Lenin blvd., 5/7
E. A. Yelisheva
Crimean Federal University n.a. V.I. Vernadsky
Russian Federation
Russian Federation
Ekaterina A. Yelisheva
295051, Simferopol, Lenin blvd., 5/7
А. М. Beitullaev
Crimean Federal University n.a. V.I. Vernadsky
Russian Federation
Russian Federation
Asan M. Beitullaev
295051, Simferopol, Lenin blvd., 5/7
K. N. Koryanova
Рyatigorsk Medical Pharmaceutical Institute of Volgograd Medical State University of Minzdrav of Russia
Russian Federation
Russian Federation
Kseniya N. Koryanova, candidate of pharmaceutical sciences
357532, Рyatigorsk, Kalinin ave., 11
References
1. Andrade V.H., Mata A.M., Borges R.S., Costa-Silva D.R., Martins L.M., Ferreira P.M., CunhaNunes L.C., Silva B.B. Current aspects of polycystic ovary syndrome: A literature review. Rev. Assoc. Med. Bras (1992). 2016;62(9):867–871. doi: 10.1590/1806-9282.62.09.867
2. Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 2000;85(7):2434–2438. doi: 10.1210/jcem.85.7.6682
3. Yildiz B.O., Bozdag G., Yapici Z., Esinler I., Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. Open. 2012;27(10): 3067–3073. doi: 10.1093/humrep/des232
4. Rosenfield R.L., Ehrmann D.A. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr. Rev. 2016;37(5):467–520. doi: 10.1210/er.2015-1104
5. Norman R.J., Dewailly D., Legro R.S., Hickey T.E. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697 doi: 10.1016/S0140-6736(07)61345-2
6. Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98(12):4565–4592. doi: 10.1210/jc.2013-2350
7. Bednarska S., Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv. Clin. Exp. Med. 2017;26(2):359–367. doi: 10.17219/acem/59380
8. Demissie M., Lazic M., Foecking E.M., Aird F., Dunaif A., Levine J.E. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am. J. Physiol Endocrinol. Metab. 2008;95(2):262–268. doi: 10.1152/ajpendo.90208.2008
9. Dumesic D.A., Oberfield S.E., Stener-Victorin E., Marshall J.C., Laven J.S., Legro R.S. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr. Rev. 2015;36(5):487–525. doi: /10.1210/er.2015-1018
10. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 2004;89(6):2745– 2749. doi: 10.1210/jc.2003-032046
11. Moran C., Tena G., Moran S., Ruiz P., Reyna R., Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol. Obstet. Invest. 2010;69(4):274–280. doi: 10.1159/000277640
12. Diamanti-Kandarakis E., Kouli C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., Zapanti E.D., Bartzis M.I. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 1999;84(11):4006–4011. doi: 10.1210/jcem.84.11.6148
13. Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 2012;33(6):981–1030. doi: 10.1210/er.2011-1034
14. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endoc. Rev. 1997;18(6):774–800. doi: 10.1210/edrv.18.6.0318
15. da Silva B.B., Lopes-Costa P.V., Rosal M.A., Pires C.G., dos Santos L.G., Gontijo J.A., Alencar A.P., de Jesus Simões M. Morphological and morphometric analysis of the adrenal cortex of androgenized female rats. Gynecol. Obstet. Invest. 2007;64(1):44–48. doi: 10.1159/000098956
16. Peters H., Byskov A.G., Himelstein-Braw R., Faber M. Follicular growth: the basic event in the mouse and human ovary. J. Reprod. Fertil. 1975;45(3):559– 566. doi: 10.1530/jrf.0.0450559
17. Fortune J.E., Cushman R.A., Wahl C.M., Kito S. The primordial to primary follicle transition. Mol. Cell Endocrinol. 2000;163(1-2):53–60. doi: 10.1016/s0303-7207(99)00240-3
18. John G.B., Gallardo T.D., Shirley L.J., Castrillon D.H. Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. Dev. Biol. 2008;321(1):197–204. doi: 10.1016/j.ydbio.2008.06.017
19. Reddy P., Liu L., Adhikari D., Jagarlamudi K., Rajareddy S., Shen Y., Du C., Tang W., Hämäläinen T., Peng S.L., Lan Z.J., Cooney A.J., Huhtaniemi I., Liu K. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2008;319(5863):611–613. doi: 10.1126/science.1152257
20. Dumesic D.A., Richards J.S. Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril. 2013;100(1):23–38. doi: 10.1016/j.fertnstert.2013.02.01
21. Khashchenko E., Uvarova E., Vysokikh M., Ivanets T., Krechetova L., Tarasova N., Sukhanova I., Mamedova F., Borovikov P., Balashov I., Sukhikh G. The relevant hormonal levels and diagnostic features of polycystic ovary syndrome in adolescents. J. Clin. Med. 2020;9(6):1831. doi: 10.3390/jcm9061831
22. Balen A.H., Rutherford A.J. Managing anovulatory infertility and polycystic ovary syndrome. BMJ. 2007;335(7621):663–666. doi: 10.1136/bmj.39335.462303.80
23. Moutos D., Smith S., Zacur H. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Contraception. 1995;52(2):105–109. doi: 10.1016/s0010-7824(95)00137-9
24. Willis D.S., Watson H., Mason H.D., Galea R., Brincat M., Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J. Clin. Endocrinol. Metab. 1998;83(11):3984–3991. doi: 10.1210/jcem.83.11.5232
25. Magoffin D.A. Ovarian theca cell. Int. J. Biochem. Cell Biol. 2005;37(7):1344–1349. doi: 10.1016/j.biocel.2005.01.016
26. Edson M.A., Nagaraja A.K., Matzuk M.M. The mammalian ovary from genesis to revelation. Endocr. Rev. 2009;30(6):624–712. doi: 10.1210/er.2009-0012
27. Barbieri R.L., Makris A., Randall R.W., Daniels G., Kistner R.W., Ryan K.J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab. 1986;62(5):904–910. doi: /10.1210/jcem-62-5-904
28. Conway G.S., Jacobs H.S., Holly J.M., Wass J.A. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 1990;33(5):593–603. doi: 10.1111/j.1365-2265.1990.tb03897
29. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 2003;163(4):427–436. doi: 10.1001/archinte.163.4.427
30. Legro R.S., Kunselman A.R., Dodson W.C., Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 1999;84(1):165–169. doi: 10.1210/jcem.84.1.5393
31. Mani H., Levy M.J., Davies M.J., Morris D.H., Gray L.J., Bankart J., Blackledge H., Khunti K., Howlett T.A. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin. Endocrinol. (Oxf). 2013;373(22):2117–2128. doi: 10.1111/cen.12068
32. de Groot P.C., Dekkers O.M., Romijn J.A., Dieben S.W., Helmerhorst F.M. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum. Reprod. Update. 2011;17(4):495–500. doi: 10.1093/humupd/dmr001
33. Синдром поликистоза яичников. Клинические рекомендации. 2016. Режим доступа: https://rae-org.ru/system/files/documents/pdf/kr258_sindrom_polikistoza_yaichnikov.pdf Polycystic ovary syndrome. Clinical guidelines. 2016. Available at: https://rae-org.ru/system/files/documents/pdf/kr258_sindrom_polikistoza_yaichnikov.pdf [In Russian].
34. Tay C.T., Joham A.E., Hiam D.S., Gadalla M.A., Pundir J., Thangaratinam S., Teede H.J., Moran L.J. Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Clin. Endocrinol. (Oxf). 2018;89(5):35–553. doi: 10.1111/cen.1375
35. Menshawy A., Ismail A., Abdel-Maboud M., El-Din A.A., Elgebaly A., Gadelkarim M., Bahbah E.I., Abdelghany M.F., Samy A., Abbas A.M. Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials. J. Gynecol. Obstet. Hum. Reprod. 2019;48(9):763–770. doi: 10.1016/j.jogoh.2019.03.025
36. Schlesselman J.J. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner’s guide to meta-analysis. Hum. Reprod. 1997;12(9):1851–1863. doi: 10.1093/humrep/12.9.1851
37. Manson J.E., Rimm E.B., Colditz G.A., Willett W.C., Nathan D.M., Arky R.A., Rosner B., Hennekens C.H., Speizer F.E., Stampfer M.J. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann. Epidemiol. 1992;2(5):665–673 doi: 10.1016/1047-2797(92)90011-e
38. Rabe T., Luxembourg B., Ludwig M., Dinger J., Bauersachs R., Rott H., Mueck A.O., Albring C. Contraception and thrombophilia – a statement from the German Society for Gynecological Endocrinology and Reproductive Medicine and the Professional Association of German Gynaecologists. J. Reproduktions Med. Endokrinol. 2011;8(1):126–167. doi: 10.18370/2309-4117.2019.45.52-56
39. Hickson S.S., Miles K.L., McDonnell B.J., Cockcroft J.R., Wilkinson I.B., McEniery C.M., ENIGMA Study Investigators. Use of the oral contraceptive pill is associated with increased large artery stiffness in young women: the ENIGMA study. J. Hypertens. 2011;29(6):1155–1159. doi: 10.1097/HJH.0b013e328346a5af
40. Amiri M., Ramezani-Tehrani F., Nahidi F., Kabir A., Azizi F. Comparing the effects of combined oral contraceptives containing progestins with low androgenic and antiandrogenic activities on the hypothalamic-pituitary-gonadal axis in patients with polycystic ovary syndrome: systematic review and meta-analysis. JMIR Res. Protoc. 2018;7(4):e113. doi: 10.2196/resprot.9024
41. Azziz R. The evaluation and management of hirsutism. Obstet. Gynecol. 2003;101(5 Pt 1):995–1007. doi: 10.1016/s0029-7844(02)02725-4
42. Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K., Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol. 1995;15(7):821–826. doi: 10.1161/01.atv.15.7.821
43. Watanabe R.M., Azen C.G., Roy S., Perlman J.A., Bergman R.N. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J. Clin. Endocrinol. Metab. 1994;79(5):1277– 1283. doi: 10.1210/jcem.79.5.7962320
44. Plewig G., Cunliffe W.J., Binder N., Höschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80(1):25–33. doi: 10.1016/j.contraception.2009.02.016
45. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., Schünemann H.J., GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336 (7650): 924–926. doi: 10.1136/bmj.39489.470347
46. Jung-Hoffmann C., Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am. J. Obstet. Gynecol. 1987;156(53):199–203. doi: 10.1016/0002-9378(87)90238-9
47. Winkler U.H., Sudik R. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception. 2009;79(1):15– 23. doi: 10.1016/j.contraception.2008.08.011
48. Cibula D., Fanta M., Vrbikova J., Stanicka S., Dvorakova K., Hill M., Skrha J., Zivny J., Skrenkova J. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum. Reprod. 2005;20(1):180–184. doi: 10.1093/humrep/deh588
49. Franks S. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin. Endocrinol. (Oxf). 2011;74(2):148–151. doi: 10.1111/j.1365-2265.2010.03934.x
50. Velazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43(5):647–654. doi: 10.1016/0026-0495(94)90209-7
51. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–10273. doi: 10.1158/0008-5472.CAN-06-1500
52. Unlühizarci K., Keleştimur F., Bayram F., Sahin Y., Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 1999;51(2):231–236. doi: 10.1046/ j.1365-2265.1999.00786
53. Crave J.C., Fimbel S., Lejeune H., Cugnardey N., Déchaud H., Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J. Clin. Endocrinol. Metab. 1995;80(7):2057–2062. doi: 10.1210/jcem.80.7.7608255
54. Crosignani P.G., Colombo M., Vegetti W., Somigliana E., Gessati A., Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum. Reprod. 2003;18(9):1928–1932. doi: 10.1093/humrep/deg367
55. Clark A.M., Ledger W., Galletly C., Tomlinson L., Blaney F., Wang X., Norman R.J. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. 1995;10(10):2705–2712. doi: 10.1093/oxfordjournals.humrep.a135772
56. Wang A., Mo T., Li Q., Shen C., Liu M. The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. Endocrine. 2019;64(2):220– 232. doi: 10.1007/s12020-019-01860-w
57. Kujawska-Luczak M., Szulinska M., Skrypnik D., Musialik K., Swora-Cwynar E., Kregielska-Narozna M., Markuszewski L., Grzymislawska M., Bogdanski P. The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance. J. Physiol. Pharmacol. 2018;69(5):738–745. doi: 10.26402/jpp.2018.5.08
58. McDuffie J.R., Calis K.A., Booth S.L., Uwaifo G.I., Yanovski J.A. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814–822. doi: 10.1592/phco.22.11.814.33627
59. Escobar-Morreale H.F., Botella-Carretero J.I., Alvarez-Blasco F., Sancho J., San Millán J.L. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 2005;90(12):6364–6369. doi: 10.1210/jc.2005-1490
60. Cena H., Chiovato L., Nappi R.E. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J. Clin. Endocrinol. Metab. 2020;105(8):2695–2709. doi: 10.1210/clinem/dgaa285
61. Coskun T., Sloop K.W., Loghin C., Alsina-Fernandez J., Urva S., Bokvist K.B., Cui X., Briere D.A., Cabrera O., Roell W.C., Kuchibhotla U., Moyers J.S., Benson C.T., Gimeno R.E., D’Alessio D.A., Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol. Metab. 2018;(18):3–14. doi: 10.1016/j.molmet.2018.09.009
62. Frias J.P., Bastyr E.J., Vignati L., Tschöp M.H., Schmitt C., Owen K., Christensen R.H., DiMarchi R.D. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell. Metab. 2017;26(2):343–352. doi: 10.1016/j.cmet.2017.07.011
63. Henderson S.J., Konkar A., Hornigold D.C., Trevaskis J.L., Jackson R., Fritsch Fredin M., Jansson-Löfmark R., Naylor J., Rossi A., Bednarek M.A., Bhagroo N., Salari H., Will S., Oldham S., Hansen G., Feigh M., Klein T., Grimsby J., Maguire S., Jermutus L., Rondinone C.M., Coghlan M.P. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 2016;18(12):1176–1190. doi: 10.1111/dom.12735
64. Zhou J., Cai X., Huang X., Dai Y., Sun L., Zhang B., Yang B., Lin H., Huang W., Qian H. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects. Eur. J. Med. Chem. 2017;138:1158–1169. doi: 10.1016/j.ejmech.2017.07.046
65. Müller T.D., Finan B., Clemmensen C., DiMarchi R.D., Tschöp M.H. The new biology and pharmacology of glucagon. Physiol. Rev. 2017;97(2):721–766. doi: 10.1152/physrev.00025.2016
66. Garthe I., Raastad T., Refsnes P.E., Koivisto A., Sundgot-Borgen J. Effect of two different weight-loss rates on body composition and strength and powerrelated performance in elite athletes. Int. J. Sport Nutr. Exerc. Metab. 2011;21(2):97–104. doi: 10.1123/ijsnem.21.2.97
67. Vuylsteke V., Chastain L.M., Maggu G.A., Brown C. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs RD. 2015;15(3):227–232. doi: 10.1007/s40268-015-0099-3
68. Yaribeygi H., Maleki M., Sathyapalan T., Jamialahmadi T., Sahebkar A. Molecular mechanisms by which imeglimin improves glucose homeostasis. J. Diabetes Res. 2020;(2):1–5. doi: 10.1155/2020/8768954
69. Paoli A., Mancin L., Giacona M.C., Bianco A., Caprio M. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. J. Transl. Med. 2020;18(1):104. doi: 10.1186/s12967-020-02277-0
70. Jensterle M., Kravos N.A., Ferjan S., Goricar K., Dolzan V., Janez A. Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocr. Connect. 2020;9(1):44–54. doi: 10.1530/EC-19-0449
71. Hallakou-Bozec S., Vial G., Kergoat M., Fouqueray P., Bolze S., Borel A.L., Fontaine E., Moller D.E. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes. Metab. 2021;23(3):664–673. doi: 10.1111/dom.14277
72. Papaetis G.S., Filippou P.K., Constantinidou K.G., Stylianou C.S. Liraglutide: New perspectives for the treatment of polycystic ovary syndrome. Clin. Drug Investig. 2020;40(8):695–713. doi: 10.1007/s40261-020-00942-2
73. Abdalla M.A., Deshmukh H., Atkin S., Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther. Adv. Endocrinol. Metab. 2020; 2042018820938305. doi: 10.1177/2042018820938305
Review
Views:
443
Email this article 